Go Pro
OTCMKTS:LYPHF

Luye Pharma Group (LYPHF) Stock Price, News & Analysis

$0.27 0.00 (0.00%)
As of 09/4/2026

About Luye Pharma Group Stock (OTCMKTS:LYPHF)

Advanced

Key Stats

Today's Range
$0.27
$0.27
50-Day Range
$0.20
$0.32
52-Week Range
$0.20
$0.33
Volume
N/A
Average Volume
1.23 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Luye Pharma Group Ltd. is a China-based pharmaceutical company headquartered in Yantai, Shandong Province. Established in 1994, the company specializes in the research, development, manufacturing and marketing of a broad portfolio of medicaments and health-care products. Luye Pharma structures its operations across three main segments: innovative drugs, generic drugs and over-the-counter (OTC) health and wellness products. Through in-house R&D and strategic collaborations, the company aims to address unmet medical needs in both domestic and international markets.

The company’s product offerings encompass key therapeutic areas such as oncology, cardiovascular disease, gastroenterology and respiratory illnesses. Among its flagship products is S-1, an oral chemotherapy agent indicated for gastrointestinal cancers. Luye Pharma’s generic portfolio includes cardiovascular and antibiotic drugs that cater to significant volume markets in China. On the OTC side, the firm markets vitamin supplements and nutritional products designed for everyday health maintenance, leveraging an expanding sales network that reaches hospitals, retail pharmacies and e-commerce platforms.

Over more than two decades of operations, Luye Pharma has invested in building a vertically integrated supply chain with manufacturing facilities accredited under both Chinese and international quality standards. The company’s global footprint has grown to include commercial subsidiaries and distribution partnerships across Asia-Pacific, Europe and North America, reflecting its ambition to serve patients beyond its domestic base. Luye Pharma’s ongoing R&D pipeline features several clinical-stage candidates, underscoring its strategic focus on innovation.

Management at Luye Pharma emphasizes a balanced approach of organic growth and targeted alliances to accelerate late-stage drug development and market access. By maintaining a diversified product mix and further advancing its R&D capabilities, the company seeks to strengthen its position as a leading biopharmaceutical enterprise emerging from China’s rapidly evolving healthcare sector.

AI Generated. May Contain Errors.

Receive LYPHF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Luye Pharma Group and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LYPHF Stock News Headlines

Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the largest mineral reserve in the country - enough gold for a new Fort Knox, enough copper to rebuild the U.S. electric grid 25 times over. The Trump administration has previously staked positions in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth - each time shares moved higher. A landmark policy decision expected before November 3 could reprice this stock from $2 to $20 or more within a year.tc pixel
Luye Pharma Gains FDA Approval for New CNS Drug Trials
Luye Pharma Converts Convertible Bonds to Shares
Luye Pharma Converts $25 Million of Tranche A Bonds
See More Headlines

LYPHF Stock Analysis - Frequently Asked Questions

Luye Pharma Group's stock was trading at $0.3903 at the beginning of 2026. Since then, LYPHF shares have decreased by 30.8% and is now trading at $0.27.

Shares of LYPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:LYPHF
CIK
N/A
Phone
N/A
Fax
N/A
Employees
5,234
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (OTCMKTS:LYPHF) was last updated on 9/6/2026 by MarketBeat.com Staff.
From Our Partners